Hidradenitis suppurativa is a long‑lasting skin condition that causes painful, inflamed lumps under the skin, often in areas such as the armpits or groin. In this study the medicine adalimumab, given as a small injection under the skin, is being tested against the usual treatment of the antibiotic doxycycline taken by mouth. Both groups may also use a topical cream containing Resorcinol as part of standard skin care.
The purpose of the trial is to find out whether early use of adalimumab can lower the chance that the condition becomes severe disease compared with standard care. Participants who have non‑severe Hidradenitis suppurativa but are considered at high risk for worsening are randomly assigned to receive either the injection or the antibiotic. The study follows them for about two years, with regular clinic visits to check the skin and overall health. “Severe disease” is defined by either a classification called Hurley stage 3, which means many connected tunnels and lumps across the affected area, or an IHS4 score of 11 or higher, a simple tally of the number of nodules, abscesses and tunnels.
After an initial screening, participants start their assigned treatment and continue it for up to 104 weeks, returning to the clinic at set intervals for safety checks and to monitor any changes in their skin condition. The study does not involve any additional procedures beyond these routine visits.
Denmark 
